Brain Tissue Collection for Neuropathological Studies - Full Text View

Sponsored by:	National Institute of Mental Health (NIMH)
Information provided by:	National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:	NCT00001260

Purpose

The purpose of this study is to collect and study the brain tissue of deceased individuals to learn more about the nervous system and mental disorders. Information gained from donated tissue may lead to better treatments and potential cures for nervous system and mental disorders.

This study will ask relatives of deceased individuals to donate the brains of their deceased relatives to allow further study of neurological and psychiatric disorders....

Condition
Bipolar Disorder Depression Anxiety Disorders Schizophrenia Tourette's Syndrome Brain Diseases

Genetics Home Reference related topics: familial encephalopathy with neuroserpin inclusion bodies familial paroxysmal nonkinesigenic dyskinesia Tourette syndrome

MedlinePlus related topics: Anxiety Bipolar Disorder Brain Diseases Child Mental Health Depression Mental Health Schizophrenia Suicide Tourette Syndrome

U.S. FDA Resources

Study Type:	Observational
Official Title:	Brain Procurement for the Neuropathology Section, CBDB

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment:	2000
Study Start Date:	May 1990

Detailed Description:

The knowledge of how affected tissue deviates from normal control tissue is an integral part of fully understanding a neurological or psychiatric disorder. The purpose of this protocol is to establish a coordinating program with the pathology departments of the Washington, D.C. and metropolitan area hospitals and local medical examiner's offices for the donation of brain tissue.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

INCLUSION CRITERIA:

Brain tissue is needed from individuals suffering from a variety of neuropsychiatric disorders, especially schizophrenia, but also anxiety disorders, suicide, bipolar disorder, depression, Tourette's Syndrome, drug addictions (PCP, cocaine, alcohol, heroin or the like) and any form of dementia. In addition, brains from normal individuals without a history of neuropsychiatric disease will be needed for controls.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00001260

Contacts

Contact: Joel E. Kleinman, M.D.

(301) 402-7909

kleinmaj@intra.nimh.nih.gov

Locations

United States, District of Columbia
Office of the Chief Medical Examiner	Recruiting
Washington, District of Columbia, United States, 20003
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike	Recruiting
Bethesda, Maryland, United States, 20892
United States, Virginia
Office of the Chief Medical Examiner	Recruiting
Fairfax, Virginia, United States, 22032

Sponsors and Collaborators

National Institute of Mental Health (NIMH)

More Information

NIH Clinical Center Detailed Web Page This link exits the ClinicalTrials.gov site

Publications:

Meyer-Lindenberg A, Straub RE, Lipska BK, Verchinski BA, Goldberg T, Callicott JH, Egan MF, Huffaker SS, Mattay VS, Kolachana B, Kleinman JE, Weinberger DR. Genetic evidence implicating DARPP-32 in human frontostriatal structure, function, and cognition. J Clin Invest. 2007 Mar;117(3):672-82. Epub 2007 Feb 8.

Law AJ, Lipska BK, Weickert CS, Hyde TM, Straub RE, Hashimoto R, Harrison PJ, Kleinman JE, Weinberger DR. Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5' SNPs associated with the disease. Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6747-52. Epub 2006 Apr 17.

Egan MF, Straub RE, Goldberg TE, Yakub I, Callicott JH, Hariri AR, Mattay VS, Bertolino A, Hyde TM, Shannon-Weickert C, Akil M, Crook J, Vakkalanka RK, Balkissoon R, Gibbs RA, Kleinman JE, Weinberger DR. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12604-9. Epub 2004 Aug 13.

Study ID Numbers:	900142, 90-M-0142
Study First Received:	November 3, 1999
Last Updated:	July 18, 2008
ClinicalTrials.gov Identifier:	NCT00001260
Health Authority:	United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):

Schizophrenia
Neuropathology
Neurochemistry
Substance Abuse
Bipolar Disorder
Aging
Normal Development
Depression
Anxiety Disorders

Suicide
Dementia
Depression
Bipolar Disorder
Neuropsychiatric Disorders
Suicide
Tourette's Syndrome
Normal Controls
Schizophrenia

Study placed in the following topic categories:

Basal Ganglia Diseases
Suicide
Brain Diseases
Neurodegenerative Diseases
Tics
Schizophrenia
Affective Disorders, Psychotic
Heredodegenerative Disorders, Nervous System
Mental Disorders
Movement Disorders
Mental Disorders Diagnosed in Childhood
Psychotic Disorders
Dementia

Schizophrenia and Disorders with Psychotic Features
Depression
Ganglion Cysts
Bipolar Disorder
Central Nervous System Diseases
Tourette Syndrome
Tic Disorders
Depressive Disorder
Behavioral Symptoms
Anxiety Disorders
Genetic Diseases, Inborn
Mood Disorders
Gilles de la Tourette's syndrome

Additional relevant MeSH terms:

Pathologic Processes
Disease
Syndrome
Nervous System Diseases

ClinicalTrials.gov processed this record on January 30, 2009